By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 231.69 |
Change Today | $ -2.15 |
% Change | -0.92 % |
52 Week High | $297.83 |
52 Week Low | $190.52 |
Volume | 747,882 |
Shares Issued | 144.90m |
Market Cap | $33,572m |
RiskGrade | 259 |
Strong Buy | 9 |
Buy | 14 |
Neutral | 11 |
Sell | 0 |
Strong Sell | 0 |
Total | 34 |
Time | Volume / Share Price |
16:00 | 159,764 @ $231.69 |
15:59 | 100 @ $231.70 |
15:59 | 100 @ $231.61 |
15:59 | 100 @ $231.58 |
15:59 | 100 @ $231.54 |
You are here: research